Skip to content

TMD Online Program for Pain Management

Mobile Application Treatment for TMD: Feasibility Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05862870
Enrollment
21
Registered
2023-05-17
Start date
2022-12-01
Completion date
2023-08-31
Last updated
2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TMD/Orofacial Pain

Brief summary

This is a proposal for an administrative supplement to the parent study, Individualized Assessment and Treatment Program for TMD: Coping as a Mechanism (U01 DE028520). The parent study is currently engaged in exploring the extent to which the training of coping skills per se is an important mechanism of psychosocial treatment. The current project seeks to lay the groundwork for expanding the range of treatment mechanisms examined to include therapeutic relationship factors (therapist support, empathy, acknowledgment). The present supplemental study will provide instruction for individual patient pain management via an online application, with no therapist or counselor assistance. The aim is to determine the extent to which treatment-related outcomes (including adherence and pain) may be influenced by therapist support factors.

Detailed description

Psychosocial treatments have been effective for temporomandibular disorders (TMD), but the mechanisms of action for these treatments are unclear. Most studies of psychosocial treatment, including the parent U01, have focused on relatively specific psychosocial mechanisms, including coping skills acquisition, pain management self-efficacy, decrease in catastrophizing, increased mindfulness, acceptance, and readiness to change behavior to ameliorate pain. The 2 therapist-delivered treatments in the parent study are packaged CBT or Individualized Assessment and Treatment (IATP). Left untested in this study are common therapeutic factors that often emerge as influential in pain outcome research. These common, non-specific therapeutic factors include (especially): the therapeutic alliance; interpretation and understanding; emotional expression; reinforcement; information; and reassurance and support. Because both conditions of the parent U01 involve similar levels of therapist involvement, therapist support and other treatment-non-specific variables cannot be tested clearly. One way to assess these factors is to introduce a pain treatment that explicitly does not contain these factors; i.e., a treatment that does not employ therapists or require supervision by health care professionals. There are currently no studies published in which therapist-led treatments have been compared to a mobile application-based treatment. The Investigators therefore propose to pilot test a mobile application treatment condition (painTrainer©) added as an additional treatment condition to the parent study, and provided to 20 patients in the coming year. This condition will deliver the content of the CBT condition of the parent study, but will do so with no therapist contact. If this mobile application is found credible and acceptable it may be used in additional comparisons with treatments conducted by therapists. Thus at some point it will be possible to parse the effects of cognitive-behavioral treatment content per se and therapist support factors. An additional benefit of testing such a mobile application is that it might in the future provide a means to expand the reach of pain management professionals to remote and underserved populations.

Interventions

BEHAVIORALpainTRAINER

patient self-administered pain management web application

Sponsors

National Institute of Dental and Craniofacial Research (NIDCR)
CollaboratorNIH
UConn Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Feasibility study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age at least 18 years * Complaint of either bilateral or unilateral pain, scoring \> 3 on a 11-point pain scale (scored from 0 to 10), in the area of the temporomandibular joint * Pain has persisted for a period of at least 3 months by patient self-report. Pain may be constant or intermittent.

Exclusion criteria

* Contraindications to TMD treatment (as determined by the consulting oral surgeon) * Inadequate fluency in English * History of prior surgery for TMD * Receiving concurrent treatment for orofacial pain (including orthodontic or physical therapy) * Have a condition that requires the use of an oral appliance (e.g., sleep apnea) * Diagnosed as having pain of neuropathic or odontogenic origin * History of rheumatoid disease or autoimmune disease (e.g., rheumatoid arthritis; lupus) currently being treated with anti-inflammatory drugs * History of kidney disease or current kidney issues * Extensive anatomical destruction or deterioration of the TM joint * Current treatment of chronic pain issue with anti-inflammatories (e.g., Indomethacin; methotrexate; dexamethasone) or opioid analgesics * Carrying a diagnosis of psychosis (as per self-report on Quick Screen) * Pregnant or anticipating pregnancy (due to prescription of NSAIDs)

Design outcomes

Primary

MeasureTime frameDescription
Treatment Feasibility8 monthsTreatment is deemed feasible if 20 persons are recruited with 8 months and complete the program. This number of patients recruited over this time period would indicate that the program is attractive to the target patient population. If this number finish the program, it would indicate that the program was a feasible means of intervention.
The Treatment Credibility/Expectancy Questionnaire3 monthsThe Treatment Credibility/Expectancy Questionnaire is composed of 4 questions that assess treatment credibility, or the extent to which a treatment seems logical and able to address patient complaints. The credibility scores may range from 4 to 36, with higher scores indicating greater endorsement of credibility.

Secondary

MeasureTime frameDescription
Patient Pain: Change in Graded Chronic Pain Scale Characteristic Pain Intensity (GCPS-CPI) Scorebaseline to 3 months after treatmentGraded Chronic Pain Scale Characteristic Pain Intensity (GCPS-CPI) score: GCPS-CPI is made up of 3 questions asking the patient to rate their pain Now, at its worst, and on average over the past 30 days. Scores on the index may range from 0 to 30, with higher scores indicative of greater characteristic pain. Outcome is measured in change from baseline.

Countries

United States

Participant flow

Recruitment details

21 persons with TMD/orofacial pain of at least 3mo duration were recruited through advertisements and referrals from local dentists

Participants by arm

ArmCount
painTRAINER Pain Management Web Application
This is a patient-administered pain management training program delivered in 10 sessions over 8 weeks. Each session is composed of different skills useful for managing chronic pain. Each session is also accompanied by recommendations for skills practice to be done between sessions. painTRAINER: patient self-administered pain management web application
21
Total21

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up3

Baseline characteristics

CharacteristicpainTRAINER Pain Management Web Application
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
5 Participants
Age, Categorical
Between 18 and 65 years
16 Participants
Age, Continuous42.0 years
STANDARD_DEVIATION 1.8
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Graded Chronic Pain Scale5.17 units on a scale
STANDARD_DEVIATION 2.02
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
White
18 Participants
Region of Enrollment
United States
21 participants
Sex: Female, Male
Female
17 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 18
other
Total, other adverse events
0 / 18
serious
Total, serious adverse events
0 / 18

Outcome results

Primary

The Treatment Credibility/Expectancy Questionnaire

The Treatment Credibility/Expectancy Questionnaire is composed of 4 questions that assess treatment credibility, or the extent to which a treatment seems logical and able to address patient complaints. The credibility scores may range from 4 to 36, with higher scores indicating greater endorsement of credibility.

Time frame: 3 months

ArmMeasureValue (MEAN)Dispersion
painTRAINER Pain Management Web ApplicationThe Treatment Credibility/Expectancy Questionnaire21 score on a scaleStandard Deviation 5.6
Primary

Treatment Feasibility

Treatment is deemed feasible if 20 persons are recruited with 8 months and complete the program. This number of patients recruited over this time period would indicate that the program is attractive to the target patient population. If this number finish the program, it would indicate that the program was a feasible means of intervention.

Time frame: 8 months

Population: 21 persons were recruited, supporting treatment feasibility

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
painTRAINER Pain Management Web ApplicationTreatment Feasibility18 Participants
Comparison: Frequency count of patients retained in treatment.p-value: 0.050% CI: [20, 20]count
Secondary

Patient Pain: Change in Graded Chronic Pain Scale Characteristic Pain Intensity (GCPS-CPI) Score

Graded Chronic Pain Scale Characteristic Pain Intensity (GCPS-CPI) score: GCPS-CPI is made up of 3 questions asking the patient to rate their pain Now, at its worst, and on average over the past 30 days. Scores on the index may range from 0 to 30, with higher scores indicative of greater characteristic pain. Outcome is measured in change from baseline.

Time frame: baseline to 3 months after treatment

ArmMeasureValue (MEAN)Dispersion
painTRAINER Pain Management Web ApplicationPatient Pain: Change in Graded Chronic Pain Scale Characteristic Pain Intensity (GCPS-CPI) Score1.7 score on a scale: decrease in pain scoreStandard Deviation 2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026